Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PTAFR | P25105 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155865 | 1.00 | EPHX1 (0.60) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL7155873 | 1.00 | EPHX1 (0.60) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL11052003 | 0.97 | EPHX1 (0.64) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL6479195 | 0.93 | EPHX1 (0.59) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL11741674 | 0.92 | EPHX1 (0.50) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL9247243 | 0.91 | EPHX1 (0.52) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL9283476 | 0.89 | EPHX1 (0.50) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL9286366 | 0.89 | EPHX1 (0.50) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL10445291 | 0.87 | EPHX1 (0.53) | EPHX1ALDH1A1CYP1A2PPARGPTAFR | |
| SCHEMBL10445195 | 0.87 | EPHX1 (0.53) | EPHX1ALDH1A1CYP1A2PPARGPTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | claimed |
| EP-1123095-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023071-A9 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE INC (US) | 2000-09-14 | — | — | WO | claimed |
| WO-2000023071-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| EP-0322033-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1989-06-28 | — | — | EP | claimed |
| JP-3086877-A | — | — | None | — | — | JP | disclosed |
| JP-4352745-A | — | — | None | — | — | JP | disclosed |
| JP-5092963-A | — | — | None | — | — | JP | disclosed |
| US-20090018209-A1 | CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENESIS | EMORY UNIVERSITY | 2009-01-15 | — | — | US | disclosed |
| CN-100427609-C | Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis | UNIV CALIFORNIA (US) | 2008-10-22 | — | — | CN | disclosed |
| CN-101089231-A | Electrolytic oxidation coupling of aryl-1,3-dicarbonyl compound and oxolane type high efficient PAF antagonist (anti)-2-5 II (3,4,5 trimethoxyphenyl) oxolane and synthesis method of its analogue | YUNAN UNIV (CN) | 2007-12-19 | — | — | CN | disclosed |
| US-7074388-B2 | Water stabilized medicinal aerosol formulation | KOS LIFE SCIENCE, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| EP-0322033-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| EP-0199324-A2 | New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists | MERCK & CO. INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4595693-A | Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists | MERCK & CO., INC. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4595693-A | Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists | MERCK & CO., INC. (US) | 1986-06-17 | — | — | US | disclosed |
| US-4539332-A | PLATELET ACTIVATION FACTOR | MERCK & CO., INC. (US) | 1985-09-03 | — | — | US | disclosed |
| EP-0144804-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf-antagonists | MERCK & CO. INC. (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0144804-A2 | New 2,5-diaryl tetrahydrofurans and analogs thereof as paf-antagonists | MERCK & CO. INC. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | ALOX5, ALOX5AP, ALOX15 | EPHX1 506/4885ALDH1A1 175/4885CYP1A2 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.